Figures & data
Figure 1. Motolimod is a selective TLR8 agonist that activates myeloid dendritic cells (mDC), resulting in the production of mediators that recruit and activate other inflammatory cells in the tumor microenvironment. Additionally, motolimod increases NK mediated antibody-dependent cell-mediated cytotoxicity (ADCC), and augments the presentation of tumor-derived antigens to the adaptive immune system.
![Figure 1. Motolimod is a selective TLR8 agonist that activates myeloid dendritic cells (mDC), resulting in the production of mediators that recruit and activate other inflammatory cells in the tumor microenvironment. Additionally, motolimod increases NK mediated antibody-dependent cell-mediated cytotoxicity (ADCC), and augments the presentation of tumor-derived antigens to the adaptive immune system.](/cms/asset/7ef45d01-a877-4804-b8ba-ecb00f016d9c/koni_a_1126037_f0001_c.gif)